Pfizer, Inc. (PFE)
NYSE • Healthcare
May 20, 2026 at 16:00 UTC
About Pfizer, Inc.
Pfizer, Inc. is a pharmaceutical company that discovers, develops, and supplies medicines and vaccines used in clinical practice worldwide. The operating model links science with delivery: research feeds trials, approvals lead to scaled production, and medical education supports appropriate use. Manufacturing and quality systems favor continuity, so once therapies enter practice, supply stays steady. Field teams focus on safety, labeling clarity, and guidance that fits real workflows in hospitals and clinics. Access programs and country teams adapt to local rules while holding to common standards. The goal is simple and long-term: turn evidence into dependable options that clinicians can trust and patients can live with. Within healthcare, Pfizer’s role is to make new treatments feel workable in daily care.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Pfizer, Inc.'s Technical Indicators Summary
PFE looks neutral with offsetting signals across timeframes and mixed confirmation from volume. Price is near the short-term averages and essentially in line with the 200-day EMA around 25.8, while RSI and other momentum measures sit in neutral ranges and MACD is slightly negative. ADX shows limited trend strength and ATR indicates modest volatility, while OBV and VWAP are mildly supportive. The balance of indicators points to consolidation rather than a directional bias. Technical takeaway: Neutral — price action is contained near key averages with no clear trend confirmation.
| Indicator | Value |
|---|---|
RSI (14) | 44.26 |
Stochastic %K (14, 3, 3) | 27.42 |
CCI (20) | -48.92 |
WPR (14) | -53.21 |
Momentum (10) | -0.61 |
MFI | 42.99 |
MACD Level (12, 26) | -0.38 |
Bollinger Bands | $25.20 - $27.13 |
ATR (14) | $0.53 (2.03%) |
ADX (14) | 18.80 |
OBV | 494,916,427 |
VWAP | $25.89 |
Classic Pivot Point | $25.62 |
Fibonacci Pivot Point | $25.62 |
Exponential Moving Averages | $25.83 - $26.52(5 indicators) |
Simple Moving Averages | $25.78 - $26.85(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
By the close, PFE remained slightly above yesterday’s 25.66, with a small 0.49% gap leaving it around 25.79. The session wrapped with neutral sector performance (-0.12%), offering little macro push or pull. PFE ticks higher on news its next-gen pneumonia vaccine showed strong antibody responses in early trials.
Price Change
from $25.79 close
+$0
Trading Volume
Below avg (37.4M)
29.3M
vs S&P 500 Today
Underperforming Market
-0.93%
52-Week Position
Mid-range
50.1%
Updated: May 20, 2026 at 20:05 UTC
Quote Summary
PFE Headlines
Ghana rejects US health data deal
May 2, 2026
Key corporate and policy moves on Apr. 24
April 24, 2026
Goldman’s Top Healthcare Picks Gain Fresh Catalysts
March 15, 2026
Institutional Moves in Major U.S. Equities
March 12, 2026